Horizon and ATCC Sign Global Licensing and Distribution Agreement
News Aug 14, 2012
Horizon Discovery Ltd (Horizon) has announced that it has signed a licensing and distribution agreement with the American Type Culture Collection (ATCC) for a select set of panels of X-MAN™ isogenic cell lines.
Under the terms of the agreement ATCC will provide Horizon’s products to its academic and not-for-profit customers as a part of or in conjunction with ATCC Tumor Cell Panels, for non-commercial research only.
The agreement excludes distribution in Japan or distribution of X-MAN™ isogenic cell lines in isolation.
Horizon’s range of over 450 X-MAN cell lines is the world’s first source of genetically-defined and patient-relevant human cell lines, accurately modeling the disease-causing mutations found in cancer patients.
The cell lines were created using the Company’s proprietary and highly precise rAAV gene-editing technology, GENESIS™, with which scientists are able to alter any endogenous gene sequence of a human or mammalian cell line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes.
Dr Raymond Cypess, CEO, ATCC, commented: “Horizon’s X-MAN cell line panels are a great complement for ATCC Tumor Cell Panels and will be a valuable resource for our customers. The ability to work with accurate disease model cell lines is of great benefit, particularly in oncology research where many mutations studied are rare, and reliable sources of patient-derived cell lines are scarce.”
“We are delighted that ATCC has chosen to work with us to expand the network of academic and not-for-profit institutions that has access to X-MAN cell lines,” said Dr Darrin Disley, CEO, Horizon.
Dr Disley continued, “X-MAN cells are already being widely used by academia and industry to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance. We look forward to seeing the progress in oncology research that increased adoption will bring about.”
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.